Dosing strategies for gene therapies
The original goal of gene therapy was to deliver a single administration that would maintain therapeutic effectiveness over a patient’s lifetime. This ‘one and done’ model appears to have worked for some gene therapies, with promising follow-up data evidenced. However, in some instances, including gene therapies for hemophilia, a single dose may not be enough, and redosing may be required.
In this article, our gene therapy experts at Health Advances, Parexel’s commercial strategy group, outline considerations for ’one-and-done’ versus redosing therapies.
Related Insights
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Blog
Advancing rare disease research: Exploring opportunities for Bayesian methods with FDA’s upcoming guidance
Jun 17, 2025
Blog
SITC Crisis in Clinical Research Virtual Summit – Collaborating to Drive Change
Aug 24, 2022
Blog
Early Scientific Advice in cost effectiveness markets – how to navigate it and is it worth it?
Jun 14, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
The New Frontier of Innovative Therapies: Navigating What's Next
Jan 12, 2023
Blog
Innovative modeling method could speed patient access to critical IO therapies
Jan 4, 2023
Podcast
Driving change in Cell & Gene Therapies: Key learnings from the SITC Virtual Summit
Sep 19, 2022
Blog
U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?
Aug 17, 2022
Related Insights
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Blog
Advancing rare disease research: Exploring opportunities for Bayesian methods with FDA’s upcoming guidance
Jun 17, 2025
Blog
SITC Crisis in Clinical Research Virtual Summit – Collaborating to Drive Change
Aug 24, 2022
Blog
Early Scientific Advice in cost effectiveness markets – how to navigate it and is it worth it?
Jun 14, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
The New Frontier of Innovative Therapies: Navigating What's Next
Jan 12, 2023
Blog
Innovative modeling method could speed patient access to critical IO therapies
Jan 4, 2023
Podcast
Driving change in Cell & Gene Therapies: Key learnings from the SITC Virtual Summit
Sep 19, 2022
Blog
U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?
Aug 17, 2022